Patent SG-11201903911U-A (SG)
Title: Combinations of fgfr4 inhibitors and bile acid sequestrants
Inventor: FAIRHURST ROBIN ALEC
IPC: A61K31/506
Filed: 2017-11-01
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 1110101011111 011101 0 011111111111111111111111111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/083603 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: Declarations under Rule 4.17: A61K 31/4545 (2006.01) A61P 35/00 (2006.01) A61K 31/506 (2006.01) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/IB2017/056787 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 01 November 2017 (01.11.2017) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,222 02 November 2016 (02.11.2016) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: FAIRHURST, Robin Alec; c/o Novartis Phar- ma AG, Klybeck, 4002 Basel (CH). GRAUS PORTA, Di- ana; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). KINYAMU-AKUNDA, Jacqueline; c/o Novartis Pharma- ceuticals Corporation, One Health Plaza, East Hanover, — 07936 (US). MAHL, Andreas Joerg; c/o Novartis Phar- ma AG, Klybeck, 4002 Basel (CH). MANENTI, Luigi; c/o = - Novartis Pharma AG, Klybeck, 4002 Basel (CH). WEISS, Andreas; c/o Novartis Pharma AG, Klybeck, 4002 Basel =_ (CH). WOLF, Armin; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). WUERSCH, Kuno; c/o Novartis Pharma = AG, Klybeck, 4002 Basel (CH). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (81) — CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, — HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = — = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = _ _ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = — Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = _ 1-1 0 en , tD cr) GC O_ 0 (54) Title: COMBINATIONS OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS 1-1 0 (57) : The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, N to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side- C::) effects associated with FGFR4 inhibition therapy.